SCHEMBL895849

SCHEMBL895849

O=C(CC(=O)Nc1ccccc1F)Nc1ccc(Oc2ccnc3cc(-c4cccc(CN5CCOCC5)c4)sc23)c(F)c1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.63
MET P08581 17/20 0.63
LCK P06239 1/20 0.54
YES1 P07947 1/20 0.54
LYN P07948 1/20 0.54
HCK P08631 1/20 0.54
FGR P09769 1/20 0.54
SRC P12931 1/20 0.54
EPHA3 P29320 1/20 0.54
FLT3 P36888 1/20 0.54
SYK P43405 1/20 0.54
BTK Q06187 1/20 0.54
DDR1 Q08345 1/20 0.54
DDR2 Q16832 1/20 0.54
MST1R Q04912 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL895974 0.94 KDR (0.65) KDRMETLCKYES1LYN
SCHEMBL18516648 0.90 MST1R (0.56) KDRMETLCKYES1LYN
SCHEMBL18516710 0.89 KDR (0.53) KDRMETLCKYES1LYN
SCHEMBL10272697 0.88 MET (0.62) KDRMETMST1R
SCHEMBL3565580 0.86 MET (0.72) KDRMET
SCHEMBL18487307 0.86 KDR (0.50) KDRMETLCKYES1LYN
SCHEMBL896417 0.85 MET (0.68) KDRMET
SCHEMBL306770 0.82 MET (0.69) KDRMET
SCHEMBL306650 0.81 MET (0.57) KDRMETMST1R
SCHEMBL3570323 0.81 MET (0.73) KDRMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957498-B1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC (CA) 2017-02-15 EP disclosed
EP-1957498-B1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC (CA) 2017-02-15 EP disclosed
US-8329726-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-12-11 US disclosed
US-8329726-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-12-11 US disclosed
US-20120083482-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC. 2012-04-05 US disclosed
US-20120083482-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC. 2012-04-05 US disclosed
US-8093264-B2 Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-01-10 US disclosed
US-8093264-B2 Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-01-10 US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 KDR 4/4885MET 2/4885LCK 582/4885
US-20120083482-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING HGF, MET, KDR KDR 3/4885MET 2/4885LCK 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.